BriaCell Therapeutics Corp News - BCT

BriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of ‘Eye-Bulging’ Tumor

12.0 months average overall survival benefit, including 13.4 months in patients with 2+ HLA matches and 12.5...

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BERKELEY, Calif. and VANCOUVER, British Columbia, May 19, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics...

BriaCell to Participate at Upcoming Conferences and Appoints Senior R&D Director

BERKELEY, Calif. and VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics...

BriaCell Announces Closing of Over-Allotment Option in Connection with U.S. Public Offering, Bringing Total Gross Proceeds to...

BERKELEY, Calif. and VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics...

BriaCell Therapeutics Presents Clinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021

Clinical and pathological data presented from the clinical trials of Bria-IMT™ alone and in combination with...

BriaCell Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2021

Clinical and pathological findings from clinical trial of the Bria-IMT™ regimen alone and in combination with...

BriaCell Announces Closing of US$25 Million Public Offering

BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 26, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics...

BriaCell Announces Pricing of US$25 Million Public Offering and Nasdaq Listing

BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 23, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics...

BriaCell Presents Clinical Data at 2021 Keystone Symposium

Clinical and pathological findings presented from the clinical trials of Bria-IMT™ alone or in combination with...

BriaCell Announces Presentation at the 2021 Keystone Symposia Conference: Emerging Cell Therapies

Clinical and pathological data from clinical trial of the Bria-IMT™ regimen alone or in combination with immune...

BriaCell Presents Clinical Data at the 2020 San Antonio Breast Cancer Symposium®

Disease control and survival data is presented from the clinical trials of Bria-IMT™ alone or in combination...

BriaCell Appoints Martin Schmieg to Board of Directors

BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics...

BriaCell Therapeutics Corp. Closes Debt Financing

BERKELEY, Calif., and VANCOUVER, British Columbia, Nov. 17, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics...

BriaCell Announces Collaboration with the National Cancer Institute

BriaCell and National Cancer Institute to collaborate on Bria-OTS™, BriaCell’s off-the-shelf personalized...

BriaCell Breast Cancer Survival Data: 13.3 Months Versus 7.2-9.8 Months

Overall Survival of 13.3 months in patients, including 14 months in patients with Grade I/II tumors, suggesting...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

BriaCell Therapeutics Corp (BCT)

Professional-Grade Tools, for Individual Investors.

BCT News

BriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of ‘Eye-Bulging’ Tumor

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell to Participate at Upcoming Conferences and Appoints Senior R&D Director

BriaCell Announces Closing of Over-Allotment Option in Connection with U.S. Public Offering, Bringing Total Gross Proceeds to...

BriaCell Therapeutics Presents Clinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021

BriaCell Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2021

BriaCell Announces Closing of US$25 Million Public Offering

BriaCell Announces Pricing of US$25 Million Public Offering and Nasdaq Listing

BriaCell Presents Clinical Data at 2021 Keystone Symposium

BriaCell Announces Presentation at the 2021 Keystone Symposia Conference: Emerging Cell Therapies

BriaCell Presents Clinical Data at the 2020 San Antonio Breast Cancer Symposium®

BriaCell Appoints Martin Schmieg to Board of Directors

BriaCell Therapeutics Corp. Closes Debt Financing

BriaCell Announces Collaboration with the National Cancer Institute

BriaCell Breast Cancer Survival Data: 13.3 Months Versus 7.2-9.8 Months

BCT Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

BriaCell Therapeutics Corp (BCT) News

BriaCell Therapeutics Corp (BCT)

Professional-Grade Tools, for Individual Investors.

BCT News

BriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of ‘Eye-Bulging’ Tumor

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell to Participate at Upcoming Conferences and Appoints Senior R&D Director

BriaCell Announces Closing of Over-Allotment Option in Connection with U.S. Public Offering, Bringing Total Gross Proceeds to...

BriaCell Therapeutics Presents Clinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021

BriaCell Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2021

BriaCell Announces Closing of US$25 Million Public Offering

BriaCell Announces Pricing of US$25 Million Public Offering and Nasdaq Listing

BriaCell Presents Clinical Data at 2021 Keystone Symposium

BriaCell Announces Presentation at the 2021 Keystone Symposia Conference: Emerging Cell Therapies

BriaCell Presents Clinical Data at the 2020 San Antonio Breast Cancer Symposium®

BriaCell Appoints Martin Schmieg to Board of Directors

BriaCell Therapeutics Corp. Closes Debt Financing

BriaCell Announces Collaboration with the National Cancer Institute

BriaCell Breast Cancer Survival Data: 13.3 Months Versus 7.2-9.8 Months

BCT Discussion

Your Recent History